CYP51 was tested as a therapeutic target for CD and in this context anti-fungal triazole derivatives that inhibit this enzyme such as ravuconazole, prodrug E1224 (Fosravuconazole), VNI [(R)-N-(1-(2,4-dichlorophenyl)-2-(1H-imidazol-1-yl)ethyl)-4-(5-phenyl-1,3,4-oxadiazol-2-yl)benzamide)] [22], VFV [(R)-N-(1-(3,4′-difluoro-[1,1′-biphenyl]-4-yl)-2-(1H-imidazol-1-yl)ethyl)-4-(5-phenyl-1,3,4-oxadiazol-2-yl) (benzamide] [23] and posaconazole exhibited properties suitable for the treatment of CD. This evidence concerns the gene CYP51A1 and Cowden disease.